Nektar Therapeutics has concluded target enrolment in the Phase IIb REZOLVE-AA trial of its investigational biologic therapy, ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lemaitre Vascular (LMAT – Research Report), ...

William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report ...

BTIG analyst Julian Harrison reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) today and set a price target of $4.00. The ...

Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's ...

TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics ...

Nektar Therapeutics today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST / 12:00 p.m.

SAN FRANCISCO and NEW YORK - Nektar Therapeutics (NASDAQ: NASDAQ:NKTR), a clinical-stage biotechnology company currently trading at $0.93 per share with a market capitalization of $173 million ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.40 per share a year ago. These ...

Nektar Therapeutics is waiting on multiple data readouts for its lead drug bempegaldesleukin paired with strategic partner Bristol-Myers Squibb’s checkpoint inhibitor Opdivo, but that hasn’t ...

The biggest firm on the list is Nektar Therapeutics, which is developing the promising immunotherapy NKTR-214. The report values San Francisco-based Nektar at $17 billion thanks to its multi ...

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.